Login to Your Account

Clinic Roundup

Wednesday, March 13, 2013
• Lithera Inc., of San Diego, said the first patient was treated with LIPO-202 (salmeterol xinafoate for injection) in its 500-patient Phase IIb RESET trial. LIPO-202 is Lithera's lead candidate designed to produce localized reduction of subcutaneous fat.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription